Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
Menu
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
  • Donate
  • Register
  • Login
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
Menu
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
  • Donate
  • Register
  • Login
  • Anxiety, Depression
Loading...

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Abstract: The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute...
Read More

Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness

Abstract The purpose of this review is to examine human and preclinical data that are relevant to the following hypotheses. The first hypothesis is that deficient CB1R-mediated signaling results in symptoms that mimic those seen in depression. The second hypothesis is that activation of CB1R-mediated signaling results in behavioral, endocrine and other effects that are similar to those produced by currently used antidepressants. The third hypothesis is that conventional antidepressant therapies act through enhanced CB1R mediated signaling. Together the available data indicate that activators of CB1R signaling, particularly inhibitors of fatty acid amide hydrolase, should be considered for clinical trials for the treatment of...
Read More

HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation

Abstract: The hypothalamic-pituitary-adrenal (HPA) axis is involved in the pathophysiology of many neuropsychiatric disorders. Increased HPA axis activity can be observed during chronic stress, which plays a key role in the pathophysiology of depression. Overactivity of the HPA axis occurs in major depressive disorder (MDD), leading to cognitive dysfunction and reduced mood. There is also a correlation between the HPA axis activation and gut microbiota, which has a significant impact on the development of MDD. It is believed that the gut microbiota can influence the HPA axis function through the activity of cytokines, prostaglandins, or bacterial antigens of various microbial species. The activity of...
Read More

Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial

Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on symptoms of anxiety and depression. The aim of the present observational study was to assess general health in medicinal cannabis users and non-using controls with anxiety and/or depression.   Methods: Participants (368 Cannabis Users; 170 Controls) completed an online survey assessing anxiety and depressive symptoms, cannabis product use, sleep, quality of life, and comorbid chronic pain. Participants that completed this baseline survey were then invited to complete additional follow-up surveys at 3-month intervals. Baseline differences...
Read More

Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota’s Medical Cannabis Program

Read More

Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood A Systematic Review and Meta-analysis

Read More

Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy

Read More

CANNABIDIOL (CBD) Pre-Review Report

Read More

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017

IMPORTANCE The number of states legalizing marijuana for medical and recreational use is increasing. Little is known regarding how or why adults with medical conditions use it. OBJECTIVES To report the prevalence and patterns of marijuana use among adults with and without medical conditions, overall and by socio-demographic group,and to further examine the associations between current marijuana use and the types and number of medical conditions. DESIGN,SETTING, AND PARTICIPANTS This survey study used a probability sample of US adults aged 18 years and older from the 2016 and 2017 Behavioral Risk Factor Surveillance System,a telephone-administered survey that collects data from a representative sample of...
Read More

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with...
Read More
1 2 Next »

REGISTER WITH THE RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • 5040 Corporate Plaza Drive, Suite 7R, Colorado Springs, CO 80919
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2023 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer